Parents who rely on powdered infant formula have faced two linked outbreaks of infant botulism in less than a year. The FDA’s July 2026 letter to manufacturers and their supply-chain partners is the clearest signal yet that the agency wants tighter control over ingredients before another round of illnesses.
What happened
In November 2025, CDC and FDA investigated a multistate outbreak of infant botulism tied to ByHeart Whole Nutrition powdered infant formula. Forty-eight infants across 17 states were hospitalized. All ByHeart product was recalled. Testing later found Clostridium botulinum in a powdered-milk ingredient.
In April–May 2026, three infants in California, Pennsylvania, and Washington were hospitalized with the same illness after drinking Nara Organics Whole Milk Organic Powdered Infant Formula. Nara recalled every lot on 13 June 2026. Whole-genome sequencing linked the two outbreaks. Both brands used milk from Organic West Milk that was spray-dried by Dairy Farmers of America.
A separate international event involved cereulide (a toxin from Bacillus cereus) in ARA oil, an ingredient added to mimic the fatty-acid profile of breast milk. That contamination triggered downstream recalls in multiple countries.
What the FDA letter says
On 13 July 2026 the FDA wrote to every manufacturer, packager, distributor, importer, and retailer involved with infant formula or its ingredients. The letter does not create new rules. It restates existing expectations under 21 CFR Part 117:
The letter points out that Organic West Milk gave FDA an incomplete customer list during the 2025 investigation, so Nara’s manufacturers were not flagged at the time. The first Nara illness appeared roughly five months after the ByHeart recall.
Competing viewpoints
Industry groups have argued that powdered milk is a low-risk ingredient under normal processing and that voluntary testing plus existing preventive controls are sufficient. Some manufacturers note that finished-formula testing already covers Cronobacter and Salmonella, the two pathogens FDA currently requires finished product to be tested for.
Public-health advocates and pediatric infectious-disease specialists counter that spores of C. botulinum survive heat and that testing only the finished product misses contamination introduced earlier in the supply chain. They point to the genetic link between the two outbreaks and the incomplete supplier list as evidence that current verification is not enough. A petition now asks FDA to add botulism to the list of pathogens that must be tested for in infant formula; comments are due 30 October 2026.
What parents should do
If you still have any ByHeart or Nara Organics powdered formula, stop using it and follow the recall instructions on the company or FDA site. Photograph the lot number before discarding. Watch for signs of infant botulism—constipation, weak cry, poor feeding, loss of head control, floppiness—for up to a month after the last exposure. Treatment with BabyBIG should start as soon as the clinical picture fits; laboratory confirmation is not required.
For current formula use, check the FDA recalls page and the manufacturer’s site regularly. Keep the lot numbers of any formula you open. If your baby develops symptoms after consuming formula, contact a doctor and the state health department immediately.
What to watch next
FDA’s root-cause investigation is still open. The agency has already sampled 48 powdered-milk lots from four suppliers; two organic nonfat milk powders tested positive by PCR for a Clostridium carrying a botulinum toxin gene. Results of additional product and environmental testing are expected. Whether FDA will move from guidance to a formal requirement for supplier audits or finished-product botulism testing will become clearer after the October comment period closes and after any further illnesses are reported.
Until then, the practical message for parents is the same: know the lot numbers in your pantry, respond quickly to any recall, and seek care at the first sign of botulism symptoms.
Comments (0)
No comments yet.
Sign in to comment.